Neuroblastoma is a tumor of the peripheral sympathetic nervous system 1 , derived from multipotent neural crest cells (NCCs). To define core regulatory circuitries (CRCs) controlling the gene expression program of neuroblastoma, we established and analyzed the neuroblastoma super-enhancer landscape. We discovered three types of identity in neuroblastoma cell lines: a sympathetic noradrenergic identity, defined by a CRC module including the PHOX2B, HAND2 and GATA3 transcription factors (TFs); an NCC-like identity, driven by a CRC module containing AP-1 TFs; and a mixed type, further deconvoluted at the single-cell level. Treatment of the mixed type with chemotherapeutic agents resulted in enrichment of NCC-like cells. The noradrenergic module was validated by ChIP-seq. Functional studies demonstrated dependency of neuroblastoma with noradrenergic identity on PHOX2B, evocative of lineage addiction. Most neuroblastoma primary tumors express TFs from the noradrenergic and NCC-like modules. Our data demonstrate a previously unknown aspect of tumor heterogeneity relevant for neuroblastoma treatment strategies.
Nearly one in six people who die of a cancer in childhood have a neuroblastoma, a tumor of the peripheral sympathetic nervous system 1 . Several genes, including MYCN 2 , ALK [3] [4] [5] [6] and TERT 7, 8 , have been shown to act as major drivers of neuroblastoma oncogenesis. In this work, we have determined the transcriptional CRCs 9 that govern the gene expression program of neuroblastoma. CRCs, which can be defined by super-enhancer mapping of H3K27 acetylation (H3K27ac) and further sequence motif analysis, provide integrative information about cell identity 9, 10 .
We examined a panel of 25 neuroblastoma cell lines (Supplementary Table 1 ) and two primary human NCC (hNCC) lines 11 . Super-enhancers were defined by the ROSE algorithm 12 , modified to account for copy number changes. Principal component analysis (PCA) based on scores of super-enhancers identified in at least two neuroblastoma cell lines or in both hNCC lines (n = 5,975) identified two distinct groups ( Fig. 1a) : group I, with 18 neuroblastoma cell lines, and group II, comprising the GIMEN, SH-EP and GICAN neuroblastoma cell lines. Group II closely resembled the hNCC lines in this analysis. Four neuroblastoma cell lines occupied an intermediate position between groups I and II. These included the phenotypically heterogeneous SK-N-SH cell line, whereas its subclones, SH-SY5Y and SH-EP, were included in groups I and II, respectively. This result is consistent with SH-SY5Y cells displaying neurite-like processes and expressing noradrenergic biosynthetic enzymes TH and DBH (N phenotype), and SH-EP cells exhibiting a substrate-adherent S phenotype without expression of TH and DBH 13 . We also profiled the super-enhancer landscape of six patient-derived xenografts (PDXs), five of which had Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries l e t t e r s Table 2 ). All PDXs clustered with group I when included in the PCA (Fig. 1a) .
MYCN amplification (Supplementary
We then sorted super-enhancers according to median H3K27ac signal for each group (Fig. 1b,c and Supplementary Table 3) . In group I, the strongest super-enhancers comprise a set of TF loci including HAND2, PHOX2A, PHOX2B, GATA2, GATA3 and the ALK oncogene locus (Fig. 1b,d ,e and Supplementary Figs. 1 and 2) . These findings are consistent with previous super-enhancer data on a few neuroblastoma cell lines 14, 15 . PHOX2B, HAND2 and GATA3 participate in a complex TF network controlling normal sympathetic neuron specification and differentiation 16, 17 . Recurrent super-enhancers in these TFs therefore appear to be a hallmark of sympathetic cell identity. Most superenhancers of group II overlapped with super-enhancers of hNCC lines (Fig. 1c) , consistent with the results of the PCA analysis.
Our analysis found MYCN super-enhancers for 10 out of 18 cell lines in group I, with or without MYCN amplification, and for three PDXs (Supplementary Fig. 3 ). No groups linked to the MYCN or ALK status were identified in the PCA. Furthermore, supervised analysis of super-enhancer scores did not indicate super-enhancers associated with MYCN amplification or ALK mutations (Supplementary Tables 4 and 5). Cell lines with a PHOX2B mutation were observed in group I (SH-SY5Y), group II (SH-EP) and in the intermediate group (SK-N-SH).
To detect driver TFs for groups I and II, we used i-cisTarget to find DNA sequence motifs enriched in the super-enhancers with the highest score. For group I, this analysis identified a TAATYYAATTA binding motif common to several homeobox proteins, including PHOX2B and PHOX2A (Supplementary Fig. 4 ). During sympathetic nervous system development, PHOX2B regulates PHOX2A expression 18 . Both TFs are highly expressed in most neuroblastoma cell lines and primary tumors (Supplementary Fig. 5 ). PHOX2B was undetectable at the transcript and protein levels in group II and hNCC lines HAND2  HAND1  KLF7  ISL1  PHOX2A  NR3C1  BHLHE41   MAFF  GLIS3  IRF1  IRF2  IRF3  FLI1  MEF2D  PRRX1  RUNX1  RUNX2  TBX18  FOSL1  FOSL2   PHOX2B  GATA3  HAND2  HAND1  KLF7  ISL1  PHOX2A  NR3C1  BHLHE41  MAFF  GLIS3  IRF1  IRF2  IRF3  FLI1  MEF2D  PRRX1  RUNX1  RUNX2  TBX18  FOSL1 Group II   IGR-NB8  IGR-NB835  HSJD-NB011  MAP-GR-A99-NB-1  MAP-GR-B25-NB-1  MAP-IC-A23-NB-1   SJNB6  SJNB8  CLB-CAR  CLB-PE  IMR32  LAN-1  N206  SK-N-BE(2)-C   SK-N-DZ   TR14  CLB-BER-Lud   CLB-MA  NB-69  CLB-GA  SJNB1  SK-N-FI  SH-SY5Y  NB-EBc1  CHP-212  SK-N-AS  SK-N-SH  SJNB12  GIMEN  SH-EP  GICAN  hNCC rep1  hNCC i   Vinculin   PHOX2B   GICAN  NB69  CHP-212  SK-N-SH  CLB-Ber-Lud   CLB-GA  CLB-MA  CLB-PE  GIMEN  SH-EP  SH-SY5Y  SJNB1  SJNB6  SJNB12  SK-N-AS  SK-N-BE( Module  Module 1  Module 2   9  10  36  1  7  37  4  8  18  22  29  46  42  5  32  28  33  38  35  2  14  3  6  11  15  40  24  21  34  39  26  41  25  45  12  23  16  20  19  13  17  44  30  27  31  43   Cell ID   PHOX2B  GATA3  HAND2  HAND1  KLF7  ISL1  PHOX2A  NR3C1  GLIS3  IRF1  IRF2  PRRX1  RUNX1  RUNX2  TBX18  FOSL1 l e t t e r s but was expressed in all other neuroblastoma cell lines ( Fig. 1f and Supplementary Fig. 6 ). There was a corresponding lack of superenhancer at PHOX2B and no TH and DBH transcription in GIMEN, SH-EP or GICAN cells (Supplementary Fig. 7 ). i-cisTarget analysis showed enrichment in AP-1 motif in group II and the hNCC lines ( Supplementary Figs. 8 and 9 ). AP-1 is a heterodimer composed of FOS and JUN family members, both of which are expressed in immature hNCCs 11 . These results suggest that PHOX2B participates in the activity of neuroblastoma group I super-enhancers while the AP-1 TF influences the super-enhancer landscape of group II. A CRC calling algorithm 9, 19 identified PHOX2B as specific to group I, and FOSL1, FOSL2 and JUN specific to group II ( Supplementary  Fig. 10) , consistent with our i-cisTarget results. We therefore searched for TFs predicted to be in a CRC either with PHOX2B or a FOS or JUN family member (Fig. 1g) . Cell lines showing an intermediate position in the PCA had a CRC that included several TFs of sets associated with PHOX2B and FOS or JUN. Most TFs of the latter set are expressed in NCCs and/or mesenchymal neural crest derivatives. The CRCs of the six PDXs were highly similar to those of the group I cell lines (Fig. 1g) . Because super-enhancer strength correlated linearly with gene expression (Supplementary Fig. 11 ), we used the latter to further define fully connected TF modules. This analysis identified two main TF modules distinguishing groups I and II ( Fig. 1h) : module 1, which included PHOX2B, GATA3 and HAND2, and module 2, which included FOSL1 and FOSL2. These modules were anticorrelated at the gene expression level. Immunoblot analysis confirmed the coexpression of several TFs in group I or group II ( Supplementary  Fig. 12 ). Furthermore, single-cell analysis showed that the SK-N-AS and SK-N-SH cell lines were heterogeneous and comprise cells expressing TFs of module 1 or module 2 within the same population (Fig. 1i, Supplementary Fig. 13 and Supplementary Table 6) .
Taken together, these data demonstrate a novel type of heterogeneity in neuroblastoma cell lines and suggest that individual cells assume either (i) a sympathetic noradrenergic identity, characterized by a CRC module including PHOX2B, HAND2 and GATA3 and expression of the enzymes TH and/or DBH, or (ii) an NCC-like identity, characterized by expression of a distinct module including FOS and JUN family members but lacking PHOX2B and noradrenergic marker expression. Both types of identity are observed in several heterogeneous cell lines. All cell lines with MYCN amplification except one (CHP-212) had a GATA3  HAND2  HAND1  KLF7  ISL1  PHOX2A  NR3C1  BHLHE41   MAFF  GLIS3  IRF1  IRF2  IRF3  FLI1  MEF2D  PRRX1  RUNX1  RUNX2  TBX18  FOSL1  FOSL2   PHOX2B  GATA3  HAND2  HAND1  KLF7  ISL1  PHOX2A  NR3C1  BHLHE41  MAFF  GLIS3  IRF1  IRF2  IRF3  FLI1  MEF2D  PRRX1  RUNX1  RUNX2  TBX18 l e t t e r s noradrenergic identity, whereas all three identities were represented in cell lines without MYCN amplification (Fig. 1g) .
To explore whether the different identity classes seen in neuroblastoma cell lines are also characteristic of neuroblastoma primary tumors, we studied expression data from a large set of primary tumors 20 (n = 498; GEO GSE49711). Correlations between expression of the TFs of each module identified in cell line CRCs were calculated for these tumors. We observed strong positive correlations between PHOX2B, HAND2 and GATA3 expression levels in module 1. We also detected positive intercorrelations in expression of the NCC-like module TF genes (Fig. 2a) . Our analysis further indicated that expression of PHOX2B, HAND2 and GATA3 is anticorrelated with that of the NCC-like module TF genes. These results therefore confirm our observations in cell lines and further define a PHOX2B-HAND2-GATA3 noradrenergic CRC module in primary neuroblastomas. Next, we used the average expression of the two modules to explore primary tumor identity. All but two tumors showed high expression of the noradrenergic module (Fig. 2b) .
A continuum was observed from low to high values of the NCC-like module, suggesting heterogeneity of cell identity in primary tumors. The remaining two cases with low noradrenergic and high NCC-like module expression may correspond to rare cases with full NCC-like identity, as described for group II cell lines. Similarly to the cell lines ( Supplementary Fig. 14) , lower expression of the NCC-like module was observed in the majority of MYCN-amplified tumors (P = 1.01 × 10 −10 , two-sided Wilcoxon signed-rank test). A role for MYCN in downregulation of genes from this module is consistent with its promotion of peripheral neuron differentiation from multipotent avian NCC 21 .
Next, expression of the NCC-like and noradrenergic modules was evaluated in ten diagnosis-relapse sample pairs 22 . Different patterns were observed between the two disease stages (Fig. 2c) . To address a possible link between heterogeneity of cell identity and treatment response, we investigated the effect of chemotherapy on the NCClike SH-EP and noradrenergic SH-SY5Y cell lines. SH-EP cells were more resistant to the three agents used (Supplementary Fig. 15 ). 
l e t t e r s
Treatment of the parental SK-N-SH cell line with doxorubicin or cisplatin resulted in the decreased or increased expression of modules 1 and 2, respectively (Fig. 2d) . Enrichment of cells with an NCClike identity thus correlates with better drug resistance. However, we cannot exclude the possibility that treatment may also induce transdifferentiation from a noradrenergic to an NCC-like identity. The observation that tumors at relapse are not systematically enriched in NCC-like cells supports the concept of plasticity in the reversion of cell identity. This may rely on a switch from adrenergic to NCC-like identity under chemotherapy, and from NCC-like to noradrenergic after treatment. Together, these data underline the importance of targeting both types of cells during treatment.
Strong correlations among PHOX2B, HAND2 and GATA3 expression were observed in cell lines and tumors. PHOX2B directly binds HAND2 protein 23 , and PHOX2B, HAND2 and GATA3 cross-regulate during sympathetic nervous system development 16 . We therefore performed ChIP-seq analysis for these TFs in the CLB-GA neuroblastoma cell line and identified binding motifs for PHOX2B, HAND2 and GATA3 (Fig. 3a) . Binding regions for all three TFs corresponded to the H3K27ac peaks in the PHOX2B, GATA3, HAND2 and ALK super-enhancers and also in the MYCN super-enhancer (Fig. 3b,c and  Supplementary Fig. 16 ). These results therefore confirm the biological existence of the noradrenergic module, showing that PHOX2B, HAND2 and GATA3 are super-enhancer regulated and bind to one another's super-enhancers (Fig. 3d) . We next investigated the occupancy by these TFs of 4,336 super-enhancer regions predicted in at least two neuroblastoma cell lines. We ranked super-enhancer regions according to average super-enhancer score and evaluated intersection with TF binding sites. More than 90% of the strong and recurrent neuroblastoma super-enhancers were co-occupied by PHOX2B, HAND2 and GATA3 (Fig. 3e) . Additionally, positional binding analysis showed that HAND2, PHOX2B and GATA3 bind the same ~400-bplong regions within active regulatory regions (Fig. 3f) . Together, our results demonstrate that PHOX2B, HAND2 and GATA3 are master TFs, defining the super-enhancer landscape of neuroblastoma cell lines with noradrenergic identity.
It has been demonstrated that cancer dependencies can be found among super-enhancer-marked genes 19, 24 . Although missense and frameshift mutations in PHOX2B are associated with predisposition to neuroblastoma 25, 26 , its role in sporadic neuroblastoma remains poorly understood. Phox2b-deficient mice completely lack autonomic structures 17 , whereas conditional knockout of Phox2b leads to decreased neuroblast proliferation 27 . An effect of PHOX2B knockdown on neuroblastoma cell proliferation has been previously suggested 28 . To further document the consequence of PHOX2B knockdown on neuroblastoma growth, we generated a doxycyclineinducible anti-PHOX2B short hairpin RNA (shRNA) expression system in noradrenergic CLB-GA and SH-SY5Y cells. Inducible decrease of PHOX2B protein (Fig. 4a,b) resulted in significant inhibition of neuroblastoma cell growth (Fig. 4c,d and Supplementary Fig. 17 ). Decreased expression of PHOX2B in CLB-GA cells also impaired tumor growth in vivo (Fig. 4e,f and Supplementary Fig. 18 ). We then evaluated whether PHOX2B decrease was sufficient to affect the identity of the CLB-GA and SH-SY5Y cell lines. However, RNA-seq and RT-qPCR data suggested that the residual PHOX2B expression was sufficient for the cells to maintain a noradrenergic identity (Supplementary Fig. 19 ). This observation is consistent with the noradrenergic identity of the CLB-PE cell line, in which PHOX2B RNA and protein expression is low but detectable ( Fig. 1f  and Supplementary Fig. 6 ).
We observed a reduction of proliferation upon HAND2 and GATA3 knockdown in several cell lines, which is consistent with previous data on GATA3 knockdown 15 (Supplementary Fig. 20) . These results are in line with HAND2 and GATA3 controlling sympathetic neuroblast proliferation in mice 16 . Neuroblastoma cells of noradrenergic identity therefore appear to be addicted to these key lineage TFs as well as to PHOX2B 29 .
Our work provides fundamental insights into the transcriptomic and epigenomic landscape of neuroblastoma. Distinct TF networks predicate different tumor identities, corresponding to sympathetic noradrenergic or NCC-like identity. Most primary tumors comprise cells of both identities, showing a previously unknown aspect of tumor heterogeneity. Further experiments will help to determine whether targeting both identities could be a valuable strategy for neuroblastoma treatment. 
ONLINe MeTHODs
Neuroblastoma and hNCC cell lines. Neuroblastoma cell lines used in this study have been previously described 30 . Neuroblastoma cell lines were cultured at 37 °C with 5% CO 2 in a humidified atmosphere in RPMI (GE Healthcare) for CLB cell lines, SH-EP, GICAN and NB69, in IMDM (Gibco) for NB-EBc1 (according to the provided conditions), or in DMEM (GE Healthcare) for other cell lines, with 10%, 15% or 20% FCS (Eurobio) and 100 µg/ml penicillin-streptomycin (Gibco). Primary hNCC lines were grown as described 32 under bioethical approval PFS14-011 from the French Biomedical Agency for the use of human embryonic material. Briefly, cells were grown in Glutamax DMEM:F12 (Gibco) supplemented with 12% FCS (Eurobio), 100 µg/ml penicillin-streptomycin, 10 mM HEPES, 100 ng/ml hydrocortisone, 10 µg/ml transferrin, 400 pg/ml 3,3,5-thio-iodo-thyronine, 10 pg/ml glucagon, 100 pg/ml epidermal growth factor, 1 ng/ml insulin and 200 pg/ml fibroblast growth factor 2 (all products supplied by Sigma-Aldrich except EGF and FGF2, which were from Gibco). ChIP-seq and analysis. H3K27ac, PHOX2B, HAND2 and GATA3 chromatin immunoprecipitation (ChIP) was performed using the iDeal ChIP-seq kit for histones or iDeal ChIP-seq kit for transcription factors (Diagenode) using the following antibodies: ab4729 (rabbit polyclonal, Abcam) for H3K27ac, sc-376997X (mouse monoclonal), sc-9409 and sc-22206X (goat polyclonal) from Santa Cruz Biotechnology for PHOX2B, HAND2 and GATA3, respectively. Ten million cells were cross-linked with 1% formaldehyde for 10 min followed by quenching with 125 mM glycine (final concentration) for 5 min at room temperature. Chromatin was isolated by the addition of lysis buffer, and lysates were sonicated to obtain sheared chromatin to an average length of ~300 bp. ChIP was performed with chromatin of 1 million cells for H3K27ac and 3.75 million cells for TFs. The equivalent of 1% of chromatin used for TFs was kept to quantify input and reverse cross-linked 4 h at 65 °C with proteinase K. ChIP was performed overnight at 4 °C on a rotating wheel with 1 µg of antibody for H3K27ac, 2 µg for HAND2 and 5 µg for PHOX2B and GATA3. Protein A-coated magnetic beads were precleared with antibodies for 3 h at 4 °C only for TFs. After ChIP, chromatin was eluted 30 min at room temperature and reverse cross-linked 4 h at 65 °C with proteinase K. DNA was precipitated and purified with magnetic beads with the Ipure kit (Diagenode). Before sequencing, ChIP efficiency was validated by qPCR for each antibody on specific genomic regions using powerSYBR Green Master Mix (Applied Biosystems) and compared for each primer pair to the input DNA. Primers are listed in Supplementary Table 7 .
CHP-212, IMR-32, SH-SY5Y, SK-N-AS, SK-N-BE(2)C, SK-N-DZ, SK-NF-I and SK-N-SH
For PDX samples, frozen tumors were reduced to powder with a pestle and then resuspended in PBS. Cross-linking of chromatin was performed by adding 1% formaldehyde for 8 min with agitation on a rotating wheel. Lysis of cells, fragmentation of chromatin and ChIP were performed as described above for cell lines using the iDeal ChIP-seq kit for histones.
Illumina sequencing libraries were prepared from ChIP and input DNA using the TruSeq ChIP library preparation kit according to the manufacturer's protocol. Briefly, DNA was subjected to consecutive steps of end repair, dA tailing and ligation to TruSeq indexed Illumina adapters. Size selection was performed only for the H3K27ac ChIP (100-600 bp). After a final amplification step of 14 cycles, the resulting DNA libraries were quantified by qPCR (KAPA Library Quantification Kit) and sequenced on the Illumina HiSeq2500 instrument (rapid run mode; single reads, 100 nt).
ChIP-seq analysis. ChIP-seq reads were mapped to the human reference genome hg19/GRCh37 using Bowtie2 v2.1.0 (ref. 36 ). Reads of low mapping quality (Q < 20) were discarded; duplicate reads were kept in order to detect signal in genomic amplification regions. Enriched regions (peaks) were called using HMCan v1.30 (ref. 37 ) with the following parameters: minimum fragment length, 100 bp; median fragment length, 250 bp; maximum fragment length, 400 bp; small bin length, 50 bp; large bin length, 25 kb; P value threshold, 0.05; merging distance, 200 bp; number of iterations, 20; final threshold, 0.1; removing duplicates, 'false' . Regions from the hg19 ENCODE blacklist 38 were excluded from the analysis. HMCan output included ChIP density profiles corrected for the GC content and copy number bias (*.wig) and narrow and large enrichment regions further called peaks (*.bed). Density profiles were then normalized between samples with a script included in the LILY package (see below). The script rescales profiles on the basis of the median density value in the 5,000 highest peaks of each experiment, discounting the first 100 peaks, as they may correspond to amplification regions. Peaks with low signal (i.e., low HMCan score values) were also discarded on the basis of correlation values between peak length and peak signal (LILY package).
The Control-FREEC 31 algorithm was applied to input samples (default parameters; input, *.bam files) to obtain copy number profiles of each cell line. These profiles matched known copy number profiles for these neuroblastoma cell lines.
To call enhancers and super-enhancers, we used LILY, a modified version of ROSE 12, 39 . First, large H3K27ac peaks were stitched together, using a default distance of 12.5 kb, and promoter regions (±2.5 kb from the transcription start site) were excluded. Then each region received a super-enhancer score corresponding to the sum of normalized H3K27ac density values (already corrected for copy number and GC content bias by HMCan) 37 . The regions were sorted according to super-enhancer score. The threshold of the score distinguishing typical enhancers from super-enhancers was determined by ROSE. For 25 neuroblastoma cell lines, the average number of super-enhancers identified per cell line was 1,252 (s.d. 385). The highest number of super-enhancers was detected in GIMEN and SH-EP cells (1, 901 and 1,819 regions, respectively) .
ChIP-seq experiments for H3K27ac were performed once for every sample except for the CLB-GA cell line, for which the experiment was performed in two biological replicates. We used these replicate samples to document the reproducibility of super-enhancer calling and superenhancer score calculation (Supplementary Fig. 21) . Among the top 500 super-enhancers in replicate 1, 93% were annotated as active superenhancers in replicate 2.
To generate a list of neuroblastoma super-enhancers, we superimposed the super-enhancer regions predicted in the 25 cell lines and excluded regions shorter than 12 kb. To avoid stitching of several neighboring superenhancer regions into one, we separated long regions with several subpeaks into subregions, using as a threshold one-half of the median number of super-enhancers. Overall, 4,336 regions with overlapping super-enhancers detected in more than one sample were annotated as putative neuroblastoma super-enhancers (Supplementary Table 3) . Super-enhancers were assigned to the RefSeq genes (RefSeq release 78, hg19) using information about locations of topologically associating domains (TADs) in eight human cell lines 40 . Among all genes located in the same TAD as a super-enhancerand therefore possibly regulated by a super-enhancer-we selected those with the highest correlation between gene expression and super-enhancer score in the full set of samples analyzed in this study (threshold = 0.361, corresponding to an adjusted P value ('FDR') of 0.05, Supplementary Fig. 11 ). Of note, each gene can have several super-enhancer regions, and each superenhancer can be assigned to a number of genes (Supplementary Table 3 ). In total, neuroblastoma super-enhancers were assigned to 4,791 genes. Similarly, we detected and assigned to genes 1,639 super-enhancers active in both hNCC samples.
For further analysis, we kept only super-enhancer regions active in at least two neuroblastoma cell lines or hNCC samples (5,975 regions). This was done to remove cell-line-specific events and false positive predictions of superenhancer regions. To detect known TF binding motifs enriched in neuroblastoma superenhancers (cell lines of groups I and II) and super-enhancers of hNCCs, we applied the i-cisTarget 41 method to the list of 2,227, 1,850 and 1,640 valley regions in H3K27ac peaks overlapping the 100 top super-enhancers of groups I and II and hNCCs, respectively.
CRCs in the neuroblastoma cell lines, PDX samples and hNCC lines were detected by COLTRON 19 on the basis of super-enhancers with the following properties: (i) super-enhancer score correlated with gene expression in our set of 31 neuroblastoma samples, and (ii) super-enhancer region was detected in more than 2 cell lines in our study. We then parsed the files with ranked cliques to see whether a given TF was predicted to be involved in a CRC of a given sample. We kept TFs present in over 50% of cell lines from group I (n = 18) or group II (n = 3). This resulted in 69 TFs. From the COLTRON predictions, we excluded 17 TFs that were not associated with a super-enhancer in our analysis (Supplementary Fig. 10) . As motif enrichment analysis discovered a significant enrichment in homeobox and AP-1 motifs of neuroblastoma super-enhancers ( Supplementary  Figs. 4 and 8) , among these 52 TFs, we selected those that were predicted by COLTRON to occur in the same CRC as the homeobox TF PHOX2B or AP-1 TFs (JUN, JUNB, FOSL1 or FOSL2) in more than 50% of cell lines of group I or II. This resulted in 37 TFs (Fig. 1g) . Clustering of the 37 genes (hclust, McQuitty method) on the basis of the correlation of their expression defined two modules (module 1, n = 7, includes PHOX2B; module 2, n = 15, includes FOSL1 and FOSL2) (Supplementary Fig. 22) .
Motif discovery in ChIP-seq peaks of GATA3, HAND2 and PHOX2B was performed using the Position Analysis tool of the RSAT package 42 (oligonucleotide sizes: HAND2, 5 nt; GATA3, 5 nt; PHOX2B, 8 nt).
To calculate average ChIP-seq density profiles around the PHOX2B peak maximum positions, we first extracted all 2,400-bp regions centered on PHOX2B ChIP-seq binding sites and kept those that overlapped peaks of all three TFs. We obtained 14,693 such regions throughout the human genome for the CLB-GA cell line. 2,078 of them were located within the 500 strongest neuroblastoma super-enhancers. ChIP-seq density for each TF for each region was rescaled to have a maximum value of 1 corresponding to the peak maximum. We then plotted the average rescaled density for the 2,078 regions. SK-N-SH cells were plated in 6-well plates and then treated with cisplatin (7.5 µM) or doxorubicin (100 nM) for 7 d. Medium and drugs were changed every 2 d. RNAs were extracted using NucleoSpin RNA kit (Macherey-Nagel).
RNA
Doxycycline-inducible shRNA systems. PHOX2B-specific short hairpin RNAs sh1783 and sh1437 (Supplementary Table 7 ) were selected from Sigma Mission shRNA library and cloned into the pLKO-Tet-On all-in-one system 43 (Addgene). Lentiviral particles were produced in HEK293T cells, and CLB-GA cells were infected as previously described 4 . SH-SY5Y cells were incubated with viral particles for 48 h without Polybrene. Selection with puromycin (Invitrogen) at 400 ng/ml or 1 µg/ml, respectively, was performed 24 h after infection and maintained during all culture experiments, for CLB-GA and SH-SY5Y cells, respectively. PHOX2B knockdown efficacy was assessed by immunoblot 72 h after the addition of doxycycline (100 ng/ml or 1 µg/ml). For colony formation assays, 6 × 10 4 transduced cells were plated at day 0 in 6-well dishes and stained with crystal violet at day 11 (ref. 44 ).
Proliferation assays. Cells were counted in real time with an xCELLigence instrument (ACEA Biosciences) monitoring impedance across gold microelectrodes. 10 4 infected CLB-GA or SH-SY5Y cells were seeded per well of a 96-well plate in 200 µl medium containing doxycycline at 100 ng/ml or 1 µg/ml (quintuplicates per group) or no doxycycline. Medium was refreshed after 48 h. For cell counting, 2 × 10 4 infected CLB-GA or 10 5 infected SH-SY5Y cells were plated in 24-well plates in the presence or absence of doxycycline 100 ng/ml or 1 µg/ml. The numbers of living cells were counted at days 4, 7, 10 and 14 (triplicates per group) for CLB-GA and at day 8 (n = 5 or 6 technical replicates) for SH-SY5Y cells using a Vi-cell XR Cell Viability Analyzer (Beckman Coulter).
Xenotransplantation experiments and mice. 10 × 10 6 CLB-GA cells transduced with shRNA against PHOX2B (sh1783) were injected subcutaneously in the flanks of 6-week-old NSG mice (Charles River Laboratories) in an equal mix of PBS and Matrigel (BD Biosciences). When tumors reached a volume of around 170 mm 3 , mice were randomly assigned to the control (5% sucrose in drinking water) or the treatment (doxycycline (2 mg/l) and 5% sucrose in drinking water) groups. Tumor growth was monitored with a caliper every day. Mice were killed when tumors reached a volume of around 3,000 mm 3 calculated as V = a/2 × b × ((a + b)/2), with a being the largest diameter and b the smallest. Experiments were conducted in accordance with the recommendations of the European Community (86/609/EEC), the French Competent Authority, and UKCCCR (guidelines for the welfare and use of animals in cancer research). Approval for this study was received from Ministère de l'Education Nationale, de l′Enseignement Supérieur et de la Recherche (authorization number 5524-20 160531 1607151 v5).
siRNA and growth assays. HAND2 and GATA3 knockdown was performed with 20 nM siRNA (Hs_HAND2_3 #SI00131915, Hs_HAND2_6 #SI03046736, Hs_GATA3_7 #SI04202681 and Hs_GATA3_8 #SI04212446; control siRNA #1027281; Qiagen) using RNAimax transfection reagent (Thermo Fisher Scientific). The number of living cells was counted using a Vi-cell XR Cell Viability Analyzer (Beckman Coulter) (n = 5 or 6 technical replicates).
PHOX2B immunohistochemistry. Details of these experiments are provided in the Supplementary Note. Statistical analysis. To calculate P values for Pearson correlation (null hypothesis, no Pearson correlation), we implemented a one-sided permutation test. The number of permutations was 10 4 when calculating P values for correlation between super-enhancer score and gene expression (Supplementary Fig. 11 ) and 10 6 in the test for correlation between gene expression of the noradrenergic and NCC-like modules in the set of tumors (Fig. 2) . This test does not need the data to follow the normal distribution and does not require equal variation between the groups that are statistically compared. A Life Sciences Reproducibility Summary for this paper is available. 
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The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study. We used Bowtie2 v2.1.0 for read mapping
